<DOC>
	<DOCNO>NCT00921960</DOCNO>
	<brief_summary>The STOP-HF study prospective , randomize , control trial recruit asymptomatic individual risk factor leave ventricular dysfunction 50 primary care clinic Dublin south east Ireland . It design determine whether use natriuretic peptide measurement screen tool follow general cardiovascular risk factor screen reduce prevalence severity ventricular dysfunction conjunction specialist follow-up St. Vincent 's University Hospital .</brief_summary>
	<brief_title>St. Vincent 's Screening To Prevent Heart Failure Study</brief_title>
	<detailed_description>A large proportion population substantial leave ventricular dysfunction ( LVD ) symptom ( Stage B heart failure ) . For many patient , identify treat appropriately , possible prevent subsequent development heart failure ( HF ) . Although current gold standard detection LVD echocardiography , expensive impractical mass screening . Natriuretic peptide attractive candidate screen population asymptomatic LVD particularly high negative predictive value . Furthermore , study show , right setting , screen natriuretic peptide might prove cost effective combination echocardiography patient elevated level . However , common many accepted screening strategy , randomise study show screen population natriuretic peptide asymptomatic LVF alters natural history condition . From large , community base cardiovascular risk screen programme include 13,000 patient , patient catchment area St Vincent 's University Hospital invite participate STOP-HF study . The objective work determine whether use natriuretic peptide screen conjunction specialist follow-up reduce prevalence severity LVD well-defined , at-risk , primary care population . It also aim : evaluate natural history natriuretic peptide time population ; clarify optimal screen cut-offs detection LVD ; evaluate clinical , pharmacological , biochemical , genetic proteomic determinant natriuretic peptide set ; determine whether clinical benefit STOP HF screen programme , , cost effective . The study design prospective , randomised parallel group . The primary endpoint prevalence severity LVD 5 year follow . Secondary endpoint include : natural history natriuretic peptide ; relationship natriuretic peptide severity LVD , death , hospital admission ; clinical , demographic , biochemical , pharmacological , genomic , proteomic , metabolomic determinant natriuretic peptide ; screen cost-effectiveness . Participants fulfill entry criterion baseline sign inform consent randomise onto Usual Care Intervention Care arm study . Usual care define continued management patient primary care service use standard risk factor monitor intervention strategy . Intervention Care define collaborative cardiovascular management primary care specialist hospital base service . All participant receive intensive education session cardiovascular nurse risk factor advice healthy dietary lifestyle habit . There 2 year enrollment annual review 5 year follow-up primary endpoint . Permission receive extend follow period 10 year . Regardless randomisation , patient receive full clinical laboratory assessment baseline completion STOP HF study ( year 5 ) . Additionally , participant receive echocardiography assessment conclusion study . Data collection : Data collect participant regard medical history current medication . The source data collection medical record keep primary care practice patient interview . All participant receive booklet ask record visit primary care practitioner , alteration medication , new diagnosis hospital admission . Local hospital discharge record screen detect event throughout course study . Clinical Assessment : At annual interval , cardiovascular research nurse conduct clinical assessment participant include weight , abdominal girth measurement , blood pressure ( triplicate measurement lie supine position ) , heart rate observe evidence limb oedema . The nurse also question participant investigate symptom dyspnoea , angina , palpitation , orthopnoea , palpitation fatigue . Blood sample handling : Peripheral venous blood sample draw participant annual interval . Samples assess natriuretic peptide draw vacutainers contain EDTA sample assess renal function , collagen turnover lipid profile collect vacutainers contain lithium heparin . BNP Lipid profile assessment analyse use point care meter , Biosite ( Triage , USA ) Cholestech respectively . Each remain sample centrifuge 10 minute serum aliquoted stored -80°C analysis biochemical , genomic , proteomic metabolomic marker . Echocardiographic Doppler analysis : Two-dimensional echocardiographic imaging , target M-mode Doppler ultrasound measurement obtain patient . M-mode measurement take accord guideline lay American Society Echocardiography . All echocardiographic data represent mean 3 measurement different cardiac cycle . It aim STOP HF investigator single observer conduct measurement , record archive image blind fashion .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>≥40 Years age risk factor LVD include : hypertension ( medicate ≥ 1 month ) hypercholesterolemia obesity coronary artery disease ( confirm angiography ) diabetes mellitus arrhythmia valvular abnormality failure unwilling provide inform consent know ventricular dysfunction ( confirm angiography echocardiography ) previous document episode heart failure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Left ventricular dysfunction</keyword>
	<keyword>Left ventricular systolic dysfunction</keyword>
	<keyword>Left ventricular diastolic dysfunction</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>Dyslipidaemia</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Prevention</keyword>
	<keyword>Screening</keyword>
	<keyword>Cardiovascular Risk Factors</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Natriuretic Peptides</keyword>
</DOC>